Despite the fact that genitourinary defects are among the most common birth defects in newborns, little is known about their etiology. Here we analyzed children born with congenital genitourinary tract masculinization disorders by array-comparative genomic hybridization, which revealed in 1.35% of cases the presence of de novo copy number gains at Xq28 encompassing the VAMP7 gene, which encodes a vesicle-trafficking protein that is part of the SNARE complex. Transgenic mice carrying a bacterial artificial chromosome encoding human VAMP7 mimicked the defective urogenital traits observed in boys with masculinization disorders such as cryptorchidism, urethral defects and hypospadias. Transgenic mice also exhibited reduced penile length, focal spermatogenic anomalies, diminished sperm motility and subfertility. VAMP7 colocalized with estrogen receptor a (ESR1) in the presence of its cognate ligand, 17b-estradiol. Elevated levels of VAMP7 markedly intensified ESR1-potentiated transcriptional activity by increasing ESR1 protein cellular content upon ligand stimulation and upregulated the expression of estrogen-responsive genes including ATF3, CYR61 and CTGF, all of which have been implicated in human hypospadias. Hence, increased gene dosage of VAMP7, and thus higher expression levels of its protein product, enhances estrogen receptor action in male genitourinary tissues, affects the virilization of the reproductive tract and results in genitourinary birth defects in humans.
a r t i c l e s Estrogens are generally perceived to be inhibitory in male develop ment or at least to antagonize androgen action 1 , which is essential for the acquisition of a normal male phenotype 2 . Following the early steps of bipotential gonad formation and testis determination, androgens are required for the stabilization of the Wolffian duct system and its differentiation into the epididymides, vasa deferentia and semi nal vesicles. Their action is also critical for proper virilization of the external genitalia and migration of the testes through the inguinal canal into the scrotum 2 . The dependence of the masculinization of the reproductive system on androgens, however, renders this pro cess inherently susceptible to destabilization by factors interfering with hormone synthesis, metabolism or action. Such disturbances represent major etiological determinants that potentially contribute to the high prevalence of human masculinization disorders, such as hypospadias (male urethral dysmorphogenesis) and cryptorchidism (failure of testicular descent).
Epidemiological studies have provided links between inappropriate estrogen exposure and increased incidence of reproductive abnor malities in men (see refs. 3,4 for reviews on this topic). Similarly, reproductive tract lesions, such as cryptorchidism and penile defects, have been observed in male mice after prenatal and neonatal exposure to the potent nonsteroidal synthetic estrogen diethylstilbestrol [5] [6] [7] [8] . Furthermore, transgenic male mice overexpressing the enzyme aromatase, necessary for the conversion of androgens to estrogens, display several genital abnormalities, including undescended testes, subtle effects on penile development and spermatogenic arrest 9 .
The interrelationship between the androgens and estrogens working to regulate the differentiation of the male reproductive system relies on the balance between androgen and estrogen action rather than on the absolute circulating concentrations of these hormones. Any change in this homeostasis may disturb the internal milieu required for normal development and function of the male genital tract and may translate into a wide range of genitourinary disorders that can subsequently affect normal fertility. To delineate diseasecausing factors that may perturb proper hormone signaling during human urogenital devel opment, we analyzed children born with masculinization disorders using a forwardgenetics approach and identified in a subset of cases a structural genomic variant affecting the gene dosage of VAMP7. VAMP7 is a highly conserved gene 10 that encodes a transmem brane protein belonging to the soluble Nethylmaleimide-sensitive factor attachment protein receptor (SNARE) family that localizes in late endosomes and lysosomes. VAMP7 is required for heterotypic fusion of late endosomes with lysosomes and homotypic lysosomal fusion [11] [12] [13] , calciumregulated lysosomal exocytosis 14 and focal exocytosis of late endocytic vesicles during phagosome formation 15, 16 . We generated humanized bacterial artificial chromosome (BAC) transgenic mice a r t i c l e s 7 1 6 VOLUME 20 | NUMBER 7 | JULY 2014 nature medicine to infer biologically meaningful relationships between VAMP7 copy number variants and human genitourinary birth defects.
RESULTS

VAMP7 copy number gain in a subset of undermasculinized boys
We used a clinically validated comparative genomic hybridization microarray platform to analyze DNA from 116 children present ing with idiopathic cases of 46,XY disorders of sexual development (DSD), including anomalies of testicular descent and defects of penile morphogenesis 17 . We hypothesized previously that structural DNA variation is an underlying etiology for human disorders of sexual development and showed that frequent submicroscopic gains and losses of DNA segments are strongly associated with defective urogeni tal traits 17 . Among the clinically significant imbalances identified, we observed an identical copy number gain at the distal tip of the long arm of Xq28 in two unrelated subjects (Fig. 1a,b and Supplementary  Fig. 1a,b Fig. 1c,d ). This structural vari ant was secondarily confirmed by fluorescence in situ hybridization (FISH) analysis ( Fig. 1c) . When we applied a twotailed Fisher's exact test, this copy number change was more frequent in subjects present ing with congenital genitourinary defects (2 out of 116) than in control individuals without urogenital abnormalities (n = 8,951) run on the same array CGH platform (P = 2.2 × 10 −3 ). Whereas the Xq28 region had contiguous coverage on the microarray, the distal bacterial arti ficial chromosome (BAC) clone RP11479B17 was the only segment showing a copy number gain ( Supplementary  Fig. 1a,b) . The maximum size of the defect exclusively included the pseudoautosomal region 2 (PAR2), whereas the minimal criti cal interval (RP11479B17) solely encom passed VAMP7 (Supplementary Fig. 1e ). An analysis of published literature revealed that there are additional subjects who presented with syndromic cryp torchidism and/or micropenis among their clinical features together with larger Xq28 terminal duplications that also encompassed VAMP7 ( Fig. 1d and Supplementary Table 1 ).
On the basis of these observations, we hypothesized that duplica tion of the Xq28 region and, more specifically, of VAMP7 plays a role in human disorders of masculinization of the urogenital tract. Quantitative PCR analysis of VAMP7 copy number in the genome of a distinct cohort of 180 individuals presenting with isolated hypospa dias (n = 83), cryptorchidism (n = 79) or both urogenital conditions (n = 18) identified two additional subjects bearing VAMP7 copy number gain (one with isolated inguinal cryptorchidism and one with glandular hypospadias and chordee) ( Supplementary Fig. 2a) .
A second independent replication study of primary cultures of human genital skin fibroblasts from 28 subjects with congenital genitouri nary defects revealed 1 instance of midshaft hypospadias with a copy number gain of VAMP7 (3.6%) ( Supplementary Fig. 2b) , convinc ingly supporting the association of VAMP7 genomic gains with devel opmental disorders of the human genitourinary tract.
VAMP7 is expressed in the human and mouse genital tract We detected VAMP7 protein in cytoplasmic lysates from human fetal testes and ovaries ( Fig. 2a) . In adults, we detected VAMP7 mRNA throughout the human male genital tract, including the testes, epidi dymides, seminal vesicles and prostatic and penile tissues ( Fig. 2b) . A punctuate pattern of VAMP7 staining was present in the Sertoli cells, as well as in the germ cells of the seminiferous tubules of human adult testes with histologically normal spermatogenesis (Fig. 2c) . The cyto plasm of Leydig cells also showed VAMP7positive immunoreactive staining ( Fig. 2c) . In the adult human external genitalia, VAMP7 was strongly expressed in the urethral epithelium ( Fig. 2d) . Moreover, the genital mesenchyme, including corpus cavernosa and the androgen dependent penile spines of the preputial epithelium, showed high levels of VAMP7 protein ( Fig. 2e) . Similarly, fetal testes and develop ing genital tubercles in mouse embryos at gestational day 16.5 were positively stained for VAMP7 ( Fig. 2f,g) . Thus, VAMP7 mRNA and protein are present in the human and mouse genitourinary tract dur ing development and at maturity.
Increased VAMP7 gene dosage leads to genitourinary defects
We sought to investigate in vivo the impact of genetically elevated VAMP7 levels on genitourinary development and reproductive physi ology. We produced a mouse model that expresses human VAMP7 under its endogenous regulatory sequences to recapitulate the genetic gain observed in patients. We generated mutant mice through micro injection of a 159kilobase linearized BAC (clone RP11479B17) including the human VAMP7 gene into fertilized oocytes of FVB mice and obtained two independent VAMP7 founder lines, 7 and 21.
VAMP7BAC transgenic mice were viable and had normal growth and lifespan. Western blot analysis using an antibody that specifically recognizes the human VAMP7 protein confirmed the expression of the transgene in the testes of mutant mice ( Supplementary Fig. 3a ).
Using primers that recognize both human and mouse transcripts, we quantified mRNA levels of VAMP7 by quantitative RTPCR in the two lines (21 and 7) and found them to be only two to three times higher than the messenger levels of the endogenous Vamp7 in wildtype (WT) mice ( Fig. 3a) . Throughout the adult and fetal testes and exter nal genitalia, the spatial expression pattern of the transgene mirrored that of the endogenous product in the WT animals and localized to cytoplasmic compartments as expected ( Fig. 3b) . For the rest of the study, the two transgenic lines 7 and 21 were evaluated in parallel to control for potential insertion effects. Data from strain 7 are presented when identical outcomes were obtained for both lines (for line 21, see Supplementary Fig. 4 ).
Examination of individually housed VAMP7-BAC adult male mice revealed a high incidence of cryptorchid testes (87.5%; seven out of eight mice), either bilateral (85.7% for strain 7 and 57.2% for strain 21) or unilateral (14.3% for strain 7 and 42.8% for strain 21) ( Fig. 3c) . Testes were considered scrotal in location if they had to be pulled out of the scrotal sac, inguinal when superior to the scrotum but inferior to the bladder at the inguinal ring, and low abdominal or high abdominal, respectively, when they were at or superior to the level of the bladder. The testicular location in uni or bilaterally cryptorchid VAMP7BAC transgenic mice was variable, predominantly inguinal in both strains (strain 7: 7.1% scrotal, 64.3% inguinal and 28.6% low abdominal; strain 21: 21.4% scrotal, 42.9% inguinal and 35.7% low abdominal) ( Fig. 3d) . None of the cryptorchid gonads were located in a high intraabdominal position ( Fig. 3d,e ), imply ing that the androgendependent inguinoscrotal phase of testicular descent was defective in VAMP7BAC transgenic mice. Examination of the gubernaculum, a mesenchymal tissue connecting the fetal testis to the developing scrotum, revealed a slightly feminized appearance with a thinner and elongated gubernacular cord connected to the lower cauda epididymis, as compared to the rudimentary gonadal ligament in WT male siblings ( Fig. 3f) . Notably, thin and elongated gubernaculum cords have previously been seen in estrogentreated mouse embryos [18] [19] [20] [21] .
Histological analysis of genital tubercles from VAMP7BAC transgenic mice revealed variable penile defects ( Fig. 3g) . Half of the analyzed male transgenic embryos had normally developed genital tubercles with the ventral epithelial surfaces forming a closed urethral groove where epithelial surfaces fused to create the urethral seam and resulted in a true urethra. However, 16 .7% (one out of six) exhibited hypospadias, an anomaly of the ventral urethral tube closure ( Fig. 3g) . Underdeveloped baculum, abnormalities of the epitheliallined prepuce housing the penis and reduced thickness of the tunica albuginea capsule surrounding the corpora cavernosa were observed in 33.3% (two out of six) of VAMP7BAC transgenic male embryos ( Fig. 3g) . Many of the penile defects in VAMP7BAC transgenic animals resembled those observed following the prenatal or neonatal administration of estrogenic compounds in male mice [6] [7] [8] . Furthermore, anogenital distance tended to decrease in mutant VAMP7BAC transgenic male mice ( Fig. 3h) , but, more strikingly, penile length was significantly shorter in all adult transgenic animals than in their WT littermates ( Fig. 3i) .
Thus, higher levels of VAMP7 expression in the mouse male geni tourinary tract mimicked the urogenital phenotypic traits observed in patients with VAMP7 copy number gain, i.e., cryptorchidism, hypo spadias and micropenis. The VAMP7BAC transgenic mouse models suggest a causative link between VAMP7 duplication and congenital genitourinary defects in humans.
Modest impact of VAMP7 on androgen receptor action
As a VAMP7 genomic defect was present in male subjects present ing with cryptorchidism, hypospadias or micropenis, and because npg a r t i c l e s normal androgen action is crucial for penile development and testicu lar descent, we asked whether elevated levels of VAMP7 interfere with androgen action. To assess the impact of VAMP7 on androgen receptor (AR) transcriptional activity, we used a cell culture-based assay in HeLa cells using a firefly luciferase reporter gene driven by an androgenresponsive element (ARE) in the promoter of the kallikrein related peptidase 3 (KLK3 gene, which encodes a protein more com monly known in clinical diagnostics as prostatespecific antigen). Liganddependent AR transcriptional activity was suppressed by 60% with VAMP7 overexpression after transient transfection with a VAMP7 expression vector (Fig. 4a) . This observed inhibition was not a result of a decrease of AR protein levels ( Supplementary Fig. 3b ).
We observed the physical presence of VAMP7 and AR in the same protein complexes by coimmunoprecipitation assays (Fig. 4b) , suggesting possible functional interactions between these two pro teins. As VAMP7 is involved in cellular sorting 11, 12, 22 , we questioned whether VAMP7 overexpression alters the subcellular localization of AR at the time of liganddependent stimulation. Immunofluorescent staining after transient transfection of AR and/or VAMP7 in the pres ence or absence of dihydrotestosterone (DHT) revealed colocaliza tion of VAMP7 and AR in the cytoplasm upon DHT administration ( Fig. 4c) , implying a failure of efficient translocation of AR to the nucleus despite the presence of DHT. As VAMP7 localizes in the endo somes, we used RAB5A, a marker of early endosomes, to demonstrate a colocalization of AR and RAB5A in the presence of DHT (Fig. 4c) .
To determine whether AR may be mislocalized in vivo, we then analyzed the cellular distribution of AR in the testes of VAMP7BAC transgenic mice, which express the transgene in ranges far below the high doses of our transfection conditions but similar to those in the human genomic gains. In vivo, we observed AR in the cytoplasm of few, but not all, cells of testes that stained positively for AR from VAMP7BAC transgenic mice (Fig. 4d) , contrasting with its exclusive nuclear localization in the male gonads of WT littermates (Fig. 4d) .
We concluded that the observed mosaic pattern of AR subcellular distribution in the testes of VAMP7BAC transgenic mice reflects a partial interference of liganddependent shuttling of AR in vivo, probably the result of VAMP7 overexpression. Under these conditions of VAMP7 overexpression in the VAMP7-BAC transgenic mice, we examined AR recruitment to its genomic occu pancy sites in the presence of increased VAMP7 gene dosage. In vivo chromatin immunoprecipitation in testicular tissues of VAMP7BAC transgenic mice was performed using the ARE of several genes involved in AR signaling, including Fkbp4, Mafb and Fkbp5 (refs. [23] [24] [25] . Although we observed a clear in vivo binding of AR in WT testis, binding was significantly reduced in the gonads of male VAMP7BAC transgenic mice (Fig. 4e) . Consistent with the observed AR occupancy, the immunoreactivity of the androgenresponsive genes Fkbp5 and Mafb was lower in the fetal and adult genital tracts of VAMP7BAC transgenic male mice than in those of WT littermates (Fig. 4f,g) . The expression of other testicular androgen target genes such as Rhox5, Drd4, Eppin, Tubb3 and Cldn11 was examined. With the exception of a significant decrease in Cldn11 (encoding a tight junction protein at the blood-testis barrier), we did not observe any dramatic changes in the expression of these genes in the testes of VAMP7BAC transgenic mice compared to those in WT animals (Supplementary Fig. 3c) . Thus, the impact of VAMP7 on AR transcriptional activity, although a r t i c l e s apparent when examined in an in vitro cellular context, is only partial in vivo. This is reflected by subtle alterations in expression of select AR target genes. Accordingly, other signaling pathways were likely to contribute to the phenotypic anomalies observed in the VAMP7BAC transgenic mice.
Elevated VAMP7 dosage potentiates estrogen receptor action
In vivo, the balance between androgen and estrogen receptor action, as opposed to androgen action alone, is an important factor for male reproductive tract development 28 . Consequently, we focused our further investigations on the impact of VAMP7 overexpression on estrogen signaling. With a classic estrogenresponsive element driving the expression of a luciferase reporter, we observed an unexpected, massive and highly significant synergistic transcriptional effect when we cotransfected VAMP7 with ESR1 into HeLa cells in the presence of estradiol (Fig. 5a) . Under these conditions, VAMP7 increased the liganddependent protein concentration of ESR1 (Fig. 5b) , perhaps through protein stabilization or through the utilization of Fig. 3d ) or after VAMP7 overexpression in the testes of VAMP7BAC transgenic mice (Fig. 5) . The potential for a functional interaction between VAMP7 and ESR1 was further substantiated by the fact that these two proteins were physically found in the same protein com plexes ( Fig. 5c ) and colocalized in identical subcellular compartments (Supplementary Fig. 3e) .
To examine the in vivo functional interaction between VAMP7 and ESR1, we assessed the gene expression of known players involved in the estradiolmediated action in VAMP7BAC transgenic mice. Whereas expression levels were unchanged for the estrogendependent co regulators, including p160 family (Ncoa1, Ncoa2, Ncoa3), Crebbp, Kat2b, Med1, Ncor2, Carm1 and the nuclear receptors Ar and Esr1 ( Fig. 5d and Supplementary Fig. 4a ), we observed a significant upreg ulation of mRNA levels of three estrogenresponsive genes, including activating transcription factor 3 (Atf3), connective tissue growth fac tor (Ctgf) and cysteinerich angiogenic inducer 61 (Cyr61), in the tes tes of the VAMP7BAC transgenic mice ( Fig. 5d and Supplementary  Fig. 4a) . These observations are of key importance, as ATF3, CTGF and CYR61 are estrogenresponsive genes that are strongly upregu lated in patients with hypospadias [29] [30] [31] [32] [33] . Moreover, variants of ATF3 are associated with hypospadias in humans 34, 35 . Consistent with this, Atf3 protein levels were higher in fetal and adult testicular and penile tissues of VAMP7BAC transgenic animals than in the tissues of WT littermates (Fig. 5e) . Conversely, selective knockdown of VAMP7 in the human testicular embryonal carcinoma NT2/D1 cell line led to a significant decrease of ATF3 gene expression ( Fig. 5f) , confirming that VAMP7 is a positive regulator of ATF3 gene expression. Concomitantly, the expression levels of additional estrogenresponsive genes were altered in the testes of VAMP7BAC transgenic mice com pared to WT gonads (Fig. 5d) . Indeed, Nrip1 mRNA levels, directly induced by estrogen receptor action 36 , were higher in VAMP7BAC transgenic mice than in WT littermates (Fig. 5d) . The expression of Cyp19a1, which is downregulated by estradiol in the testis 37 , was lower in the testes of VAMP7BAC transgenic mice than in WT gonads ( Fig. 5d and Supplementary Fig. 4a) . Additionally, we observed higher mRNA levels of estrogen sulfotransferase (Sult1e1), an enzyme involved in the maintenance of the functional integrity of malespecific tissues against local estrogenic activity 38 , in the testes of VAMP7BAC transgenic mice than in WT animals ( Fig. 5d and  Supplementary Fig. 4a ). In line with these in vivo data, estrogen receptor signaling was among the top pathways affected following acute VAMP7 knockdown in NT2/D1 cells, as revealed by a func tional analysis of gene expression microarrays data by Ingenuity Pathway Analysis (Fig. 5g) .
Finally, the occurrence of inguinal hernias in some VAMP7BAC transgenic mice further supports our conclusions ( Fig. 5h) , as this phenotypic trait is observed with estrogen overstimulation in animal models, i.e., after administration of estrogens in male rodents 39, 40 and in aromataseoverexpressing male mice 9, 41 .
Collectively, increased gene dosage of VAMP7, a SNAREencoding gene, has a positive impact on ESR1mediated transcriptional activ ity ( Fig. 5i) and exerts a partial and inhibitory effect on AR action. ATF3, although positively induced by ESR1 action, acts as an AR corepressor by preventing its binding to target genes and inhibiting transcriptional activation 42 . This may explain the effects of VAMP7 overexpression on the altered expression of several androgen responsive genes, including Cldn11, Fkbp5 and Mafb. The dual dif ferential action of VAMP7 may partially 'estrogenize' males and subtly reduce AR action, leading to slightly feminized male reproductive development in VAMP7BAC transgenic mice. This observation pro vides a molecular explanation for the clinical picture phenotype found in our cohort of human subjects with genitourinary anomalies.
Mice with elevated levels of VAMP7 are subfertile As androgen and estrogen action are also important for spermatogen esis, we examined 6monthold male VAMP7BAC transgenic mice. Transgenic animals had small testes and focal spermatogenic deficiency a r t i c l e s resulting in subfertility ( Fig. 6 and Supplementary Fig. 4b-h) . Testis weight was reduced to about 50% compared to that of WT scrotal testes (Fig. 6a) . Epididymal and seminal vesicle weights were similar to those of WT controls (Fig. 6b,c and Supplementary Fig. 4c,d) .
The histological pattern of the adult mouse cryptorchid testes was less uniform, showing discrete foci of disrupted spermatogenesis ( Fig. 6d  and Supplementary Fig. 4e ). Arrest of spermatogenesis, sloughing of germ cells at various stages of maturation and vacuolization of Sertoli cells were evident within the affected seminiferous tubules ( Fig. 6d  and Supplementary Fig. 4e) . Large multinucleated round cells were often present in the lumen of the tubules ( Fig. 6d and Supplementary  Fig. 4e ). Serum testosterone, 17βestradiol, luteinizing hormone (Lh) and folliclestimulating hormone (Fsh) levels were not significantly different from those in WT males (Fig. 6e-h and Supplementary  Fig. 4f) . To quantify the functional consequences of the damage to the seminiferous epithelium, we measured sperm count and motil ity ( Fig. 6i and Supplementary Fig. 4g) . Although the number of caudal sperm was not significantly decreased, the total motility of sperm isolated from caudal epididymes of 6monthold VAMP7BAC transgenic mice was reduced by 75% for strain 7 and 70% for strain 21, suggesting deficient epididymal function, perhaps owing to altered hormone action ( Fig. 6i and Supplementary Fig. 4g ). Histological examination of the reproductive tissue of male VAMP7BAC trans genic mice revealed morphological alterations of the epididymis in the mice, including vacuolization of the epididymal epithelium as well as the presence of numerous round cells in the lumen of caput and cauda epididymides ( Fig. 6d and Supplementary Fig. 4e) .
To assess whether the reduced motility of caudal sperm from the VAMP7BAC transgenic males was associated with reduced fertility, we conducted a controlled mating experiment in which we mated 6weekold WT or transgenic males with 8weekold WT females. During a 4month period, VAMP7BAC transgenic males sired a similar number of litters to the WT mice. However, the litter size in the transgenic group was significantly smaller ( Fig. 6j and Supplementary Fig. 4h ).
DISCUSSION
Copynumber variants account for considerable human phenotypic variation and disease risk 43 . They exert their influence by modifying the expression of genes mapping within or close to the rearranged regions. A de novo copy number variant in 46,XY individuals with mild masculinization defects suggested a causal link of VAMP7 gene duplication to the congenital genitourinary defects. We did not find any copy number gain of VAMP7 in 8,951 control individuals, high lighting the high degree of significance for the VAMP7 copy number duplications and the strong association between VAMP7 gene dos age changes and human cryptorchidism, hypospadias and micropenis (P = 2.2 × 10 −3 ; Fisher's exact test). We initially detected a gain of VAMP7 in 4 cases out of a total of 296 patients (1.35%); then, in a second replication study, we found 1 case in 28 distinct primary cul tures of genital skin fibroblasts (3.6%). The incidence of VAMP7 gains represents the highest frequency reported to date, to our knowledge, for a genetic or genomic cause of genitourinary birth defects. Even previously identified pathogenetic mutations in genes such as INSL3, RXFP2 and AR exhibited lower frequencies ranging from 0.3% to 0.8% in individuals with disorders of sexual differentiation 44 . Additionally, the Gene Expression Omnibus (GEO) database repository of high throughput gene expression data shows that VAMP7 mRNA levels were significantly upregulated in human cryptorchid testes in two independent studies (GSE16191 and GSE25518) 45, 46 . These data substantiate our findings and support the fact that VAMP7 copy number change is a clinically significant factor in the etiology of human congenital genitourinary defects.
Although our data support a genomic basis for genitourinary birth defects, they also shed light on an unexpected molecular determinant affecting male phenotypic development. Under normal conditions, VAMP7 ensures proper membrane fusion and transport between vari ous organelles 12, 13, 22 . This study shows that VAMP7 is a dosagesensitive gene, as we detected slight differences in the magnitude of the pheno typic defects between the two VAMP7BAC transgenic lines. Indeed, line 7 mice, which had a higher level of VAMP7 expression than line 21 mice, exhibited a higher incidence of bilateral cryptorchidism, as well as a slightly more marked decrease of testis weight and litter size. Similarly, line 7 mice displayed a significant upregulation of select genes, with Atf3, Sult1e1 and Cyr61 showing the biggest differences, and Ctgf and Nrip1 revealing modest impairment. Mice from strain 21 also displayed a significant upregulation of Atf3 and Sult1e1 and a trend of increase of Cyr61 (P = 0.09), whereas expression of Ctgf and Nrip1 genes was unchanged. Our observations provide evidence that higher protein levels of VAMP7 correlate with a more severe phenotype in mice.
Elevated levels of VAMP7 enhanced estrogen receptor-driven transcription of genes including Atf3, Ctgf and Cyr61, all of which are upregulated in individuals with hypospadias 29 . The dual func tion of VAMP7 in membrane sorting and transcriptional action was previously reported for a subset of factors involved in endocytosis and endosomal trafficking such as huntingtininteracting protein 1, auxilin2, clathrin heavy chain, βarrestin1 and βarrestin2, APPL1 and APPL2 (adaptor protein containing PH domain, PTB domain and leucine zipper motif 1 and 2) and CALM (clathrin assembly protein lymphoid myeloid) [47] [48] [49] [50] [51] . Several of these endocytic proteins exert AR coregulatory characteristics [47] [48] [49] , mainly through association with transcription factors and/or facilitation of chromatin modifica tions 47, 50, 52 . Our study reinforces the concept that vesicular transport and endosomal factors are able to perturb key nuclear functions and transcriptional regulation.
We have demonstrated that elevated levels of VAMP7 can lead to an increase in liganddependent ESR1 protein content without affecting its mRNA levels and can result in a subsequent stimulation of transcriptional activity similar to the action of other previously reported proteins 53 . ESR1 stability and protein turnover are finely controlled by ubiquitination and proteosomal degradation to ensure efficient transcriptional activity of the nuclear receptor [54] [55] [56] . Recent evidence highlights the existence of crosstalk between the ubiquitinproteasome and autophagylysosome systems 57 . Perturbations in the flux through either pathway could affect the activity of the other system 58 . Given that VAMP7 is a regulator of autophagosome formation 17 , one of the potential effects of increased VAMP7 might be the perturbation of the ubiquitinproteasome path way leading to abnormal processing of select proteins, including ESR1. Although beyond the scope of this present study, the exact underlying molecular mechanisms merit further clarification.
In conclusion, genomic defects encompassing the gene encoding VAMP7 are present in a subset of humans with congenital genitourinary disorders. Alterations of the gene dosage of this vesicular trafficking factor are responsible for abnormal human and mouse male genitourinary tract development, mainly due to a marked enhancement of estrogen receptor transcriptional action. VAMP7 overexpression underlies the etiology of a subset of common disorders of male sexual differentiation. npg METHODS Methods and any associated references are available in the online version of the paper. Accession codes. Gene expression microarray data have been depos ited in the GEO database with accession number GSE56102.
